Streamline Complex Oncology Case Discussions
Eliminate fragmented WhatsApp groups and email chains. Consolidate PET-CT scans, histopathology slides, and molecular genetics in one secure environment.
PACS & DICOM Zero-Footprint Viewer
Inspect CT, MRI, and PET scans directly within the browser with multi-planar reconstruction, window leveling, and measurement tools.
Molecular Genomics & Biomarkers
Highlight actionable mutations (EGFR, ALK, KRAS, BRCA, HER2) with direct links to targeted therapy clinical trials and guidelines.
Consensus Documentation
Generate structured, sign-off-ready MDT summary notes that automatically link to the patient's EMR and ABHA record.
NCCN vs. ICMR Guideline Concordance Framework for Digital MDTs
Multidisciplinary Tumor Boards in India frequently navigate clinical divergence between resource-intensive international NCCN guidelines and the Indian Council of Medical Research (ICMR) consensus protocols tailored for resource-stratified care.
๐งฌ Molecular Biomarker & NGS Gating
While NCCN mandates routine broad-panel NGS in advanced NSCLC, ICMR prioritizes reflex single-gene PCR for actionable EGFR (Exon 19/21) and IHC for ALK before costly panels. OncoCare supports tiered biomarker tagging so panels can select appropriate lines of therapy based on financial and insurance eligibility.
๐ Generic & Biosimilar Equivalence
In accordance with ICMR oncology consensus, OncoCareโs regimen builder seamlessly incorporates DCGI-approved biosimilars (Trastuzumab, Bevacizumab, Rituximab) alongside originator biologics, allowing tumor boards to record cost-conscious treatment pathways without compromising clinical efficacy.
๐ Formal Multidisciplinary Consensus Dossier
The platform compiles individual recommendations from Medical, Surgical, and Radiation Oncologists into a single signed MDT dossier. The consensus notes rationale for regimen selection, intent (curative, neoadjuvant, or palliative), and planned reassessment intervals.